Remote Ischemic Conditioning for Acute Ischemic Stroke Treated with Mechanical Thrombectomy（RECAST-MT）
- Conditions
- Anterior Circulation Brain InfarctionAcute Ischemic Stroke
- Interventions
- Procedure: Endovascular thrombectomyDevice: 14-day remote ischemic conditioningDevice: 30-day remote ischemic conditioningDrug: Best medical management
- Registration Number
- NCT06559241
- Lead Sponsor
- Capital Medical University
- Brief Summary
For patients with acute ischemic stroke caused by large vessel occlusion, endovascular thrombectomy has been demonstrated to be the most effective therapy, as approximately 90% of the occluded vessels can be recanalized. However, less than 50% of patients could achieve functional independence, and over 15% died 90 days after stroke. Although the mismatch of successful recanalization with poor prognosis can be attributed to many factors, the infarct core formed during thrombectomy and reperfusion injury after thrombectomy may be among the most important and effective neuroprotective strategies urgently needed.
Remote ischemic conditioning (RIC) is a noninvasive strategy in which one or more cycles of brief and transient limb ischemia confer protection against prolonged and severe ischemia in distant organs. In the transient focal cerebral ischemia-reperfusion model, the application of remote ischemic conditioning before reperfusion or both before and after reperfusion reduces reperfusion injuries and the final infarct size. Because patients with acute ischemic stroke who are treated with endovascular thrombectomy can achieve a high rate of recanalization after focal ischemia, this patient population is akin to the model of transient focal cerebral ischemia-reperfusion. Furthermore, a pilot study has determined the safety and feasibility of remote ischemic conditioning in patients undergoing endovascular thrombectomy. However, whether remote ischemic conditioning could provide clinical benefits to patients with acute ischemic stroke who are treated with endovascular thrombectomy urgently needs investigations.
This study aims to investigate the safety and efficacy of remote ischemic conditioning in improving functional outcomes of patients with acute ischemic stroke treated with endovascular thrombectomy and explore the effect of treatment duration on the treatment outcome of remote ischemic conditioning.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 2105
- Age≥18 years；
- Acute ischemic stroke due to large vessel occlusion in the anterior circulation that is not suitable for intravenous thrombolytic therapy, or has contraindications to intravenous thrombolytic therapy, or treated with intravenous thrombolytic therapy without recanalization;
- Large vessel occlusion confirmed by computed tomography angiography (CTA) or magnetic resonance angiography (MRA), including the occlusion of the intracranial segment of the internal carotid artery (ICA) and M1 segment of the middle cerebral artery (MCA), is the cause of symptoms, and mechanical thrombectomy is planned within 24 hours from the time last known well;
- Baseline score of the National Institutes of Health Stroke Scale (NIHSS) ≥ 6 points;
- Patients or family members signed a written informed consent form.
- Imaging examination revealed the presence of multiple vascular supply areas of cerebral infarction (such as the simultaneous presence of infarction in both anterior and posterior circulation);
- Absence of femoral artery pulsation, extremely difficult intravascular access, or extremely tortuous large vessels, which are expected to result in the inability to undergo timely endovascular treatment;
- Difficult-to-control hypertension: continuous monitoring upon admission shows systolic blood pressure ≥180mmHg, or diastolic blood pressure ≥100mmHg;
- Coma or lethargy patients (consciousness level score ≥2 in NIHSS);
- Unable to obtain an accurate baseline NIHSS score;
- Pre-stroke modified Rankin Scale (mRS) score >1;
- Baseline ASPECTS score ≤5;
- Presence of bleeding tendency, deficiency of coagulation factors, or oral anticoagulant therapy with INR > 3.0;
- Baseline blood glucose <2.7mmol/L or >22.2mmol/L;
- Baseline platelet count < 30*10^9/L;
- Severe known renal impairment defined as requiring dialysis (hemodialysis or peritoneal dialysis), or if known creatinine clearance rate <30mL/min;
- Cranial CT or MRI shows intracranial hemorrhage;
- Cranial CT or MRI shows midline deviation and significant occupying effect;
- Clinical history, previous imaging examinations, or clinical judgment suggesting intracranial tumors, arteriovenous malformations, or intracranial arterial dissection;
- History of head injury in the past 3 months;
- History of life-threatening allergy to contrast agents, nickel, titanium metal, or their alloys;
- Pregnancy, if women of childbearing age have a positive urinary or serum β-human chorionic gonadotropin (β-hCG) test or are breastfeeding；
- The life expectancy of patients is less than 6 months, and they cannot be evaluated within 3 months;
- Limb deformity, soft tissue injury, or other conditions that affect the implementation of distant ischemia adaptation therapy;
- Participating in other ongoing clinical trials;
- Other conditions that the investigators believe are not suitable for participation in this study.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Control group Endovascular thrombectomy Patients in the control group will receive endovascular thrombectomy and the best medical management according to the guidelines. 30-day treatment group Best medical management Patients in the 30-day treatment group will receive endovascular thrombectomy and the best medical management according to the guidelines. In addition, this group will receive remote ischemic conditioning once pre-thrombectomy and twice daily for 30 days post-thrombectomy. 14-day treatment group Endovascular thrombectomy Patients in the 14-day treatment group will receive endovascular thrombectomy and the best medical management according to the guidelines. In addition, this group will receive remote ischemic conditioning once pre-thrombectomy and twice daily for 14 days post-thrombectomy. 14-day treatment group 14-day remote ischemic conditioning Patients in the 14-day treatment group will receive endovascular thrombectomy and the best medical management according to the guidelines. In addition, this group will receive remote ischemic conditioning once pre-thrombectomy and twice daily for 14 days post-thrombectomy. 14-day treatment group Best medical management Patients in the 14-day treatment group will receive endovascular thrombectomy and the best medical management according to the guidelines. In addition, this group will receive remote ischemic conditioning once pre-thrombectomy and twice daily for 14 days post-thrombectomy. 30-day treatment group 30-day remote ischemic conditioning Patients in the 30-day treatment group will receive endovascular thrombectomy and the best medical management according to the guidelines. In addition, this group will receive remote ischemic conditioning once pre-thrombectomy and twice daily for 30 days post-thrombectomy. Control group Best medical management Patients in the control group will receive endovascular thrombectomy and the best medical management according to the guidelines. 30-day treatment group Endovascular thrombectomy Patients in the 30-day treatment group will receive endovascular thrombectomy and the best medical management according to the guidelines. In addition, this group will receive remote ischemic conditioning once pre-thrombectomy and twice daily for 30 days post-thrombectomy.
- Primary Outcome Measures
Name Time Method The proportion of patients achieving a modified Rankin Scale (mRS) score of 0-2 at 90 days. 90 days after stroke. The mRS ranges from 0 to 6, with higher scores indicating worse outcomes.
- Secondary Outcome Measures
Name Time Method Two dichotomous mRS scores at 90 days (0-1 vs 2-6, 0-3 vs 4-6, 0-4 vs 5-6, 0-5 vs 6). 90 days after stroke. The mRS ranges from 0 to 6, with higher scores indicating worse outcomes.
Changes in NIHSS score from baseline to day 14 or at discharge (whichever comes earlier). 14 days or at discharge (whichever comes first) The NIHSS ranges from 0 to 42, with higher scores indicating worse outcomes.
The change of infarct volume. 72 hours after endovascular procedures. Infarct Expansion Ratio (IER, IER=infarct volume/baseline infarct volume). The infarction volume will be assessed on cranial CT or MRI imaging, and baseline infarct volume will be assessed on the CTP or baseline MRI imaging.
The ordinal distribution of mRS scores at 90 days. 90 days after stroke. The mRS ranges from 0 to 6, with higher scores indicating worse outcomes.
Score of EQ-5D-5L at 90 days. 90 days after stroke. EQ-5D-5L is a tool used to assess health status, including five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. A higher score indicates a better health status, while a lower score indicates a poorer health status.
Incidence of malignant infarction 0-90 days Malignant infarction is defined as infarction involving more than half of the affected middle cerebral artery area, a significant mass effect requiring decompressive craniectomy, and/or directly leading to death with clinical signs of brain herniation.
Cerebral infarct volume. 72 hours after endovascular procedures. The infarction volume will be assessed on cranial CT or MRI imaging.
The proportion of patients with early neurological improvement 24 hours after endovascular procedures. 24 hours after endovascular procedures. The NIHSS ranges from 0 to 42, with higher scores indicating worse outcomes. Neurological improvement is defined as the NIHSS recovering to ≤2 points or decreasing by 8 points or much higher as compared with the baseline.
All cause of death. 0-90 days The incidence of death events at any time from randomization through day 90.
Incidence of Adverse Events/Serious Adverse Events 0-90 days The incidence of other adverse events and serious adverse events at any time from randomization through day 90.
Incidence of intracranial hemorrhage. Within 14 days after endovascular procedures. Intracranial hemorrhage is defined as the demonstration of hemorrhage within brain parenchyma on head imaging, according to the criteria of the ECASS III.
Incidence of Symptomatic Intracranial Hemorrhage Within 14 days after endovascular procedures. Symptomatic intracranial hemorrhage is defined as the demonstration of hemorrhage within brain parenchyma on head imaging leading to an increase of at least 4 points in the NIHSS score, according to the criteria of the European Cooperative Acute Stroke Study III (ECASS III).
Incidence of neurological deterioration within 14 days. Within 14 days after endovascular procedures. Neurological deterioration is defined as an increase of ≥4 points in NIHSS compared to before deterioration within 14 days.
Trial Locations
- Locations (33)
Beijing Luhe Hospital affiliated to Capital Medical University
🇨🇳Beijing, Beijing, China
Beijing Fangshan District First Hospital
🇨🇳Beijing, Beijing, China
Shenzhen qianhai shekou free trade zone hospital
🇨🇳Shenzhen, Guangdong, China
South China Hospital Affiliated to Shenzhen University
🇨🇳Shenzhen, Guangdong, China
Nanning Second People's Hospital
🇨🇳Nanning, Guangxi, China
Jiamusi university hongda hospital
🇨🇳Jiamusi, Heilongjiang, China
Jiaozuo Coal Industry Group Co., Ltd. Central Hospital
🇨🇳Jiaozuo, Henan, China
Luoyang Yanshi People's Hospital
🇨🇳Luoyang, Henan, China
Henan Province People's Hospital
🇨🇳Zhengzhou, Henan, China
Xihua county people's hospital
🇨🇳Zhoukou, Henan, China
Huanggang Centralhospital
🇨🇳Huanggang, Hubei, China
Huangshi central hospital
🇨🇳Huangshi, Hubei, China
Jingmen No.1 People's Hospital
🇨🇳Jingmen, Hubei, China
Jingmen people's hospital
🇨🇳Jingmen, Hubei, China
First People's Hospital of Tianmen
🇨🇳Tianmen, Hubei, China
Wuhan University Zhongnan Hospital
🇨🇳Wuhan, Hubei, China
The First People's Hospital of Xiangyang
🇨🇳Xiangyang, Hubei, China
Yichang Central People's Hospital
🇨🇳Yichang, Hubei, China
the First People'S Hospital of Changde
🇨🇳Changde, Hunan, China
The Third Xiangya Hospital of Central South University
🇨🇳Changsha, Hunan, China
Xiangya Hospital, Central South University
🇨🇳Changsha, Hunan, China
Inner Mongolia Autonomous Region People's Hospital
🇨🇳Hohhot, Inner Mongolia Autonomous Region, China
Anshan zhangda hospital
🇨🇳Anshan, Liaoning, China
Dalian Central Hospital
🇨🇳Dalian, Liaoning, China
The Central Hospital of Shengli Oilfield
🇨🇳Dongying, Shandong, China
Liaocheng Third People's Hospital
🇨🇳Liaocheng, Shandong, China
The People's Hospital of Liaocheng Brain Hospital
🇨🇳Liaocheng, Shandong, China
Feixian county people's hospital
🇨🇳Linyi, Shandong, China
Mianyang third people's hospital
🇨🇳Mianyang, Sichuan, China
Ya 'an People's Hospital
🇨🇳Ya'an, Sichuan, China
Tianjin huanhu hospital
🇨🇳Tianjin, Tianjin, China
The Second Affiliated Hospital of Wenzhou Medical University
🇨🇳Wenzhou, Zhejiang, China
Xuanwu Hospital, Capital Medical University
🇨🇳Beijing, China